EANM position paper on the role of radiobiology in nuclear medicine

Please always quote using this URN: urn:nbn:de:bvb:20-opus-265595
  • With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear medicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations. This comprises particularly safety and efficacy of radionuclide therapies, specifically tailored to each patient. As absorbed dose rates and absorbed dose distributions in space and time are very different between external irradiation and systemic radionuclide exposure, distinct radiation-induced biological responses are expected in nuclearWith an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear medicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations. This comprises particularly safety and efficacy of radionuclide therapies, specifically tailored to each patient. As absorbed dose rates and absorbed dose distributions in space and time are very different between external irradiation and systemic radionuclide exposure, distinct radiation-induced biological responses are expected in nuclear medicine, which need to be explored. This calls for a dedicated nuclear medicine radiobiology. Radiobiology findings and absorbed dose measurements will enable an improved estimation and prediction of efficacy and adverse effects. Moreover, a better understanding on the fundamental biological mechanisms underlying tumor and normal tissue responses will help to identify predictive and prognostic biomarkers as well as biomarkers for treatment follow-up. In addition, radiobiology can form the basis for the development of radiosensitizing strategies and radioprotectant agents. Thus, EANM believes that, beyond in vitro and preclinical evaluations, radiobiology will bring important added value to clinical studies and to clinical teams. Therefore, EANM strongly supports active collaboration between radiochemists, radiopharmacists, radiobiologists, medical physicists, and physicians to foster research toward precision nuclear medicine.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: An Aerts, Uta Eberlein, Sören Holm, Roland Hustinx, Mark Konijnenberg, Lidia Strigari, Fijs W. B. van Leeuwen, Gerhard Glatting, Michael Lassmann
URN:urn:nbn:de:bvb:20-opus-265595
Document Type:Journal article
Faculties:Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin
Language:English
Parent Title (English):European Journal of Nuclear Medicine and Molecular Imaging
Year of Completion:2021
Volume:48
Issue:11
Pagenumber:3365-3377
Source:European Journal of Nuclear Medicine and Molecular Imaging 2021, 48(11):3365-3377. DOI: 10.1007/s00259-021-05345-9
DOI:https://doi.org/10.1007/s00259-021-05345-9
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:biodosimetry; biomarkers; dosimetry; radiobiology; radionuclide therapy
Release Date:2022/04/14
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International